Recursion Pharmaceuticals (RXRX) Interest Expenses (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Interest Expenses came in at $4.3 million in Q1 2026, down 18.02% YoY from $5.3 million in Q1 2025, and up 148.19% on a QoQ basis from -$9.0 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Interest Expenses (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Interest Expenses data on file, last reported at $4.3 million in Q1 2026.
- Quarterly Interest Expenses fell 18.02% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 58.41% YoY) and the FY2025 annual result came in at $665.4 million, up 42.74% from the prior year.
- Interest Expenses climbed to $4.3 million in Q1 2026, from -$9.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $25.8 million in Q2 2025 to a low of -$9.0 million in Q4 2025.
- A 5-year average of $3.4 million and a median of $394000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 47020.0% — and 2025, when it sank 367.1%.
- Tracing RXRX's Interest Expenses over 5 years: stood at $7.1 million in 2022, then plunged by 158.72% to -$4.1 million in 2023, then soared by 180.8% to $3.4 million in 2024, then tumbled by 367.1% to -$9.0 million in 2025, then jumped by 148.19% to $4.3 million in 2026.
- The last three Interest Expenses figures came in at $4.3 million (Q1 2026), -$9.0 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 309,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 309,000.00 |
| Jun 30, 2026 | 309,000.00 |
| Mar 31, 2026 | 4.32 Mn |
| Mar 31, 2026 | 4.32 Mn |
| Dec 31, 2025 | -8.96 Mn |
| Dec 31, 2025 | -8.96 Mn |
| Sep 30, 2025 | 20.25 Mn |
| Sep 30, 2025 | 20.25 Mn |
| Jun 30, 2025 | 25.83 Mn |
| Jun 30, 2025 | 25.83 Mn |
| Mar 31, 2025 | 5.27 Mn |
| Mar 31, 2025 | 5.27 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 553,000.00 |
| Sep 30, 2024 | 553,000.00 |
| Jun 30, 2024 | 394,000.00 |
| Jun 30, 2024 | 394,000.00 |
| Mar 31, 2024 | 3.96 Mn |
| Mar 31, 2024 | 3.96 Mn |